Vendor Intelligence Report: Hangzhou Mandy Biotechnology

Published 3 Jul 2026. 23-page investigative report on who is behind Hangzhou Mandy Biotechnology: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 36 Finnrick lab tests, Hangzhou Mandy Biotechnology records 25 pass / 10 fail, an overall pass rate of 69%. The useful signal is dispersion, not a brand-wide verdict. GHK-Cu is the relative bright spot, tirzepatide and retatrutide sit in the lot-verification middle, and BPC-157 is the weak directional choice. The methodology-divergence work also shows how borderline ratings can fall when grading gets stricter.

The corporate record is more consequential than a simple new-vendor warning. Registry materials support a real Hangzhou biotechnology entity dating to 2014, but the accessible scope points to stem-cell, cosmetics and traditional-medicine work, not a verified peptide-manufacturing operation. The public web record is newer: the domain appears in 2024, and archived pages show a chemical raw-materials/intermediates presentation before the current peptide-facing brand.

The most serious diligence issue is a linked offshore trading trail. A Seychelles B2B listing tied to MandyBio's website and a matching Chinese contact path markets controlled-precursor chemicals such as BMK, PMK and BDO alongside peptide-related goods. That does not prove current peptide contamination, but it sharply raises governance, legal-exposure and supply-chain-control concerns for injectable buyers.

Operationally, MandyBio looks reachable but low-assurance: multiple UK and Hong Kong WhatsApp lines, Gmail sales addresses, crypto payment terms, vendor-posted Janoshik COAs, and no strong public channel-authentication or anti-counterfeit system. The affiliate scan did not find a public X/web promo network, so the risk picture is not influencer-driven; it is identity, infrastructure and product-specific lab reliability.

Inside the full report:

  • Per-product pass/fail rates, rating trajectories and methodology-divergence charts for all 4 tested products
  • Dated evidence timeline from 2014 registry records through the 2026 field refresh
  • Archived domain-capture analysis showing the chemical-intermediates period before the peptide pivot
  • Hangzhou registry findings on business scope, controller signals, staffing and patent activity
  • Seychelles B2B listing analysis tying the offshore identity to the website and contact trail
  • Sales-channel, payment-rail, Janoshik, MESO-Rx and affiliate-scan findings

Risk assessment

  • Controlled-precursor trading-chain risk — high: Seychelles Mandybio listing tied to mandybio.com/+86 19030156835 markets BMK, PMK, BDO and pregabalin alongside peptides; severe legal and governance concern.
  • Unsupported peptide-manufacturer history and licensing risk — high: The site leans on an April 2014/factory narrative, while mandybio.com dates to 2024-08-06 and the 2014 Hangzhou entity’s recorded scope is stem-cell/cosmetics/TCM, with no peptide-manufacturing license found.
  • Opaque accountable-counterparty risk — high: Records point to Hangzhou branding, a Shijiazhuang domain registrant/web stack, Seychelles B2B identity and multiple English names; the legal seller/manufacturer is not pinned down.
  • BPC-157 quality reliability risk — high: Finnrick records BPC-157 at 49.11% with 4 tests and 2 pass / 2 fail; this is the poor-choice product in the tested catalog.
  • Retatrutide and tirzepatide lot-variability risk — medium: Retatrutide (74.51%, 13 tests, 9 pass / 4 fail) and tirzepatide (77.43%, 12 tests, 9 pass / 3 fail) are materially better than BPC-157 but still require lot verification.
  • HGH testing-evidence risk — medium: HGH evidence is vendor-commissioned Janoshik/forum material; community critiques noted single-vial testing and no documented dimer analysis.
  • Crypto-only payment-recourse risk — medium: The FAQ/forum materials list USDT, BTC, USDC and ETH, leaving buyers with little chargeback or dispute leverage.
  • Authenticity-verification and brand-confusion risk — medium: Multiple names, UK/HK/Gmail/Facebook/TikTok-style channels and no authorized-channel/anti-counterfeit policy leave buyers without strong authenticity controls.
  • Domain-expiry / channel-continuity risk — medium: WHOIS shows mandybio.com scheduled to expire on 2026-08-06; buyers should monitor renewal and avoid off-domain deal channels during any churn.